HOME

TheInfoList



Click Here for Items Related To - MDMB-CHMINACA
OR:
MDMB-CHMINACA on:   [Wikipedia]   [Google]   [Amazon]

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based
synthetic cannabinoid Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. Th ...
that acts as a potent
agonist An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ...
of the CB1 receptor, and has been sold online as a
designer drug A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. ...
. It was invented by
Pfizer Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered at The Spiral (New York City), The Spiral in Manhattan, New York City. Founded in 184 ...
in 2008, and is one of the most potent cannabinoid agonists known, with a
binding affinity In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. The etymology stems from Latin ''ligare'', which means 'to bind'. In protein-ligand binding, the ligand is usuall ...
of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.


Legal status

MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015. MDMB-CHMINACA is illegal in Germany, Switzerland as of December 2015. Sweden's public health agency suggested classifying MDMB-CHMINACA as a hazardous substance, on September 25, 2019.


See also

* AB-CHMINACA * ADB-CHMINACA *
ADB-FUBINACA ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The name ...
* MDMB-CHMICA * MDMB-FUBINACA * PX-3 (APP-CHMINACA)


References

Cannabinoids Designer drugs Indazolecarboxamides {{cannabinoid-stub